Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - OtherShares Issued
Ratios

Barinthus Biotherapeutics (BRNS) Receivables Refunds (2020 - 2023)

Barinthus Biotherapeutics' Receivables Refunds history spans 4 years, with the latest figure at $1.7 million for Q3 2023.

  • For Q3 2023, Receivables Refunds rose 17090.0% year-over-year to $1.7 million; the TTM value through Sep 2023 reached $1.7 million, up 17090.0%, while the annual FY2021 figure was $705000.0, 131.15% up from the prior year.
  • Receivables Refunds reached $1.7 million in Q3 2023 per BRNS's latest filing, up from $10000.0 in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $1.7 million in Q3 2023 to a low of $10000.0 in Q3 2022.
  • Average Receivables Refunds over 4 years is $590888.9, with a median of $542000.0 recorded in 2021.
  • Peak YoY movement for Receivables Refunds: tumbled 94.28% in 2022, then surged 17090.0% in 2023.
  • A 4-year view of Receivables Refunds shows it stood at $305000.0 in 2020, then skyrocketed by 131.15% to $705000.0 in 2021, then crashed by 98.58% to $10000.0 in 2022, then soared by 17090.0% to $1.7 million in 2023.
  • Per Business Quant, the three most recent readings for BRNS's Receivables Refunds are $1.7 million (Q3 2023), $10000.0 (Q3 2022), and $1.0 million (Q2 2022).